Chemed Corporation (CHE), the dual-engine operator straddling hospice care through VITAS Healthcare and plumbing services via Roto-Rooter, has long been a Wall Street darling for its resilient revenue streams and fat margins in essential services. But peel back the glossy fundamentals, and a contrarian lens reveals cracks: decelerating growth momentum, persistent insider selling, and a stock price that’s recently stumbled despite analyst cheerleading. Trading at levels that scream caution after dipping below recent lows, CHE’s story isn’t the endless hospice boom or unbreakable plumbing pipe dream it’s often painted as. With revenue chugging along but profitability margins compressing and executives cashing out, investors should question if this is peak cycle or prelude to a rude awakening.

Revenue Engine: Steady but Slowing Grind

Chemed’s top line has been a model of consistency, ballooning from $1.58 billion in 2016 to $2.43 billion in 2024—a robust 54% cumulative increase (about 6.7% CAGR). Revenue per employee, a key efficiency metric hovering around $150,000-$155,000 lately, underscores operational leverage, rising from $108,000 in 2016 (43% up), which matters because it flags how well the company extracts value from its ~15,000-16,000 workforce amid labor squeezes in healthcare and services. Roto-Rooter’s recession-resistant franchise—fixing leaks doesn’t wait for bull markets—paired with VITAS’s hospice demand (boosted by an aging U.S. population) drove this. Yet, drill deeper: growth tapered post-2020’s COVID-fueled spike (revenue jumped 16% to $2.08B as end-of-life care surged), settling at 7-8% annually lately. Analyst forecasts see $2.55B in 2025 (5% growth), $2.70B in 2026 (6%), and $2.82B in 2027 (4%)—respectable, but hardly explosive. Correlation here? As revenue per share climbed to $162 in 2024 (from $96 in 2016, 68% gain), share count shrank via buybacks (from 16.4M to 15M shares), juicing metrics artificially. Skeptics note: hospice faces regulatory headwinds, like the 2023 OIG reports flagging VITAS for upcoding Medicare claims, risking reimbursement cuts that could crimp future ramps.

Profitability: Peaks Passed, Margins Pinched

Earnings tell a punchier tale. Net income peaked at $319 million in 2020 (202% surge from 2016’s $109M), fueled by EBT margins hitting 19% amid pandemic efficiencies, before settling at $302 million in 2024 (178% higher than 2016, but flat YoY). EBT margin stabilized around 15-16% post-2021, down from 2020 highs—a red flag since margins reflect pricing power and cost control, critical in labor-heavy hospice (40%+ of costs). Gross margins improved steadily to 35.1% in 2024 (from 29.3% in 2016, 20% relative gain), thanks to scale, but ticked down from 2021’s 36%. ROE, a shareholder value gauge, crushed at 39% in 2020 but eased to 27% in 2024—still elite, but signaling diminishing returns on equity. Analysts predict a dip to $278M net income in 2025 (8% drop), rebounding to $315M (13% up) in 2026 and $338M (7%) in 2027, implying EPS volatility (20.1 in 2024 to 19.4 in 2025, then 23.6 in 2026). Why the wobble? Capex ticked up (projected $61M in 2025, 32% rise from 2024’s $46M), potentially for facility expansions, but free cash flow per share remains stellar at ~$25, covering it handily.

Cash generation is CHE’s secret sauce, with operating cash flow exploding to $417M in 2024 (208% from 2016), yielding FCF of $371M. Free CF/share hit $24.71 (323% gain since 2016), funding buybacks and a pristine balance sheet—net debt flipped to a $178M cash position in 2024. ROIC at 24% underscores capital efficiency, but watch working capital swings (from -$72M in 2021 to +$109M in 2024), hinting at inventory or receivable strains.

Valuation: Rich Multiples Amid Fading Tailwinds

Historically, CHE traded at premium multiples, with PE averaging 25-30x (24x lately), PS 3-4x, and PB 7-9x—pricing in growth that’s maturing. EV/Sales eased to 3.3x in 2024 (from 4.1x peak), and EV/FCF a bargain 21x given cash machine status. But stack against stock performance: shares rocketed from $125 low in 2016 to $655 high in 2024 (424% gain), outpacing revenue (54%) and EPS growth (~200%). Book value/share doubled to $74 (133%), yet a 2021 plunge (56 to 40, 30% drop) coincided with debt spike to $235M—likely buyback financing amid post-COVID optimism. Now, with recent close levels, multiples compress, but consensus still embeds optimism.

Insider Activity: Selling Pressure Mounts

Here’s the contrarian alarm: insiders are dumping. From March 2025 to November, sells totaled ~$13 million across 15+ transactions, led by CEO Kevin McNamara (multiple tranches: 1,000-3,000 shares at ~$100k+ each) and EVPs (e.g., 10,012 shares for $4.2M in Aug 2025). One paltry director buy in Aug 2025 (200 shares, $83k) barely registers. This correlates with peaks: heavy March-May selling as stock hovered high, continuing into Sep-Nov. Insiders aren’t buying the hype—often a precursor to stumbles, especially post-2020 when execs held steady amid COVID windfalls. No buys in months signals confidence erosion, contrasting analyst rosy views.

Stock Trajectory: Boom to Bump

Price action mirrors fundamentals until lately. Lows climbed from $125 (2016) to $512 (2024), highs to $655 (320%), but 2026’s recent close sits roughly flat to low-end yearly ranges, down sharply from 2024 peaks (28% off highs). This decoupling? Perhaps hospice scrutiny (DOJ probes into VITAS billing lingered into 2024) or macro plumbing slowdowns. Versus fundamentals, stock outran EPS (200% vs. 424% price gain), baking in perfection now at risk.

Outlook and Targets: Upside with Asterisks

Analysts cluster around a 22% mean upside from recent levels, spanning flat at low-end to 26% high-end—tied to revenue/EBITDA forecasts. EPS rebound to 23.6 in 2026 supports, with FCF projected at $411M (2025) to $509M (2026, 24% jump). Hospice tailwinds persist (baby boomers aging), Roto-Rooter evergreen, but I challenge: 2023-2025 Medicare audits hammered peers like Amedisys (acquired amid fallout); CHE’s not immune. Capex uptick hints expansion, but if ROIC slips below 20%, returns sour.

Risks and Contrarian Bet

Consensus ignores undercurrents: insider exodus (sells dwarf buy by 150x value), margin compression (EBT 16.4% vs. 19% peak), and regulatory shadows—VITAS faced $70M+ settlements pre-2020, echoes possible. Debt low, but buyback binge (shares down 9% since 2016) leaves less float for dips. COVID masked weaknesses; normalized world exposes hospice census volatility (employees dipped to 14k in 2021). Upside exists if execution flawless, but at 22% implied returns, I’d demand discount for risks. CHE’s no value trap, but growth story’s fraying—buy dips below flat targets, fade the rally.

(Word count: 1,128)